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Abstract The clinical benefit of eribulin versus capeci-
tabine was evaluated using health-related quality of life
(HRQoL) data from a phase 3 randomized trial in patients
with pretreated advanced/metastatic breast cancer (Clini-
calTrials.gov identifier: NCT00337103). The study popu-
lation has been described previously (Kaufman et al. in J
Clin Oncol 33:594–601, 2015). Eligible patients received
eribulin (1.4 mg/m2 intravenously on days 1 and 8) or
capecitabine (1.25 g/m2 orally twice daily on days 1–14)
per 21-day cycles. HRQoL was assessed using the Euro-
pean Organisation for Research and Treatment of Cancer
(EORTC) Quality-of-life Questionnaire-Core 30 questions
(QLQ-C30) and breast module-23 questions (QLQ-BR23),
administered at baseline through 24 months, until disease
progression or other antitumor treatment initiation. Mini-
mally important difference (MID) and time to symptom
worsening (TSW) were investigated. 1062 (96.4 %)
Patients completed the EORTC questionnaire at baseline;
overall, compliance was C80 %. Patients receiving cape-
citabine versus eribulin had significantly worse symptoms
(higher scores) for nausea/vomiting (MID 8; P\ 0.05) and
diarrhea (MID 7; P\ 0.05). Treatment with eribulin versus
capecitabine, led to worse systemic therapy side-effects
(dry mouth, different tastes, irritated eyes, feeling ill, hot
flushes, headaches, and hair loss; MID 10; P\ 0.01).
Clinically meaningful worsening was observed for future
perspective (MID 10; P\ 0.05) with capecitabine and for
systemic therapy side-effects scale (MID 10; P\ 0.01)
with eribulin. Patients receiving capecitabine experienced
more-rapid deterioration in body image (by 2.9 months)
and future perspective (by 1.4 months; P\ 0.05) com-
pared with those on eribulin; the opposite was observed for
systemic side-effects where patients receiving eribulin
experienced more-rapid deterioration than those receiving
capecitabine (by 2 months; P\ 0.05). Eribulin and
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capecitabine were found to have similar impact on patient
functioning with no overall difference in HRQoL. Patients
receiving eribulin reported worse systemic side-effects of
chemotherapy but reduced gastrointestinal toxicity com-
pared with capecitabine.
Keywords Breast cancer  Eribulin  Quality of life 
Minimally important difference  Side effects
Introduction
Despite recent advances in cancer therapies and increased
availability of treatment options, metastatic breast cancer
(MBC) remains incurable. The main treatment goals are to
achieve disease control, preferably through prolonging
overall survival (OS), and to delay or prevent debilitating
disease symptoms [1, 2]. With each additional line of
therapy, the response to chemotherapy decreases further
and the response rate may be as low as 15 % in patients
who have received up to two prior therapies, and is asso-
ciated with significant toxicity and relatively low OS [3, 4].
In this situation, the measurement of patient-reported
symptom experience and health-related quality of life
(HRQoL) can provide additional information to evaluate
and compare the efficacy and toxicity profiles of the
treatments. Further, incorporation of patient-reported out-
comes into toxicity reporting in clinical trials has been
recommended to overcome the potential underreporting of
severity of subjective adverse events by physicians in
clinical trials [5–7].
Treatment side-effects (even those of lower grade) may
adversely impact patient well-being [8, 9]. For example,
chemotherapy-induced gastrointestinal symptoms (nausea,
vomiting, and diarrhea) are not life-threatening, but are
associated with worse HRQoL [10]. In contrast, uncom-
plicated neutropenia is often not associated with significant
symptoms.
Eribulin mesylate (eribulin), a novel microtubule
dynamics inhibitor, was the first single agent shown to
improve survival in patients with heavily pretreated MBC
in the phase 3, randomized study 305/EMBRACE trial,
where patients receiving eribulin experienced 2.7 months
longer median OS than those receiving treatment of
physician’s choice (hazard ratio (HR) 0.81; 95 % confi-
dence interval (CI) 0.67–0.96; P = 0.014) [11]. HRQoL
was not assessed in the trial due to the variety of treatments
and schedules in the control arm (treatment of physician’s
choice).
HRQoL was, however, a prespecified secondary end-
point in a second phase 3, open-label, randomized trial
(study 301) that evaluated eribulin versus capecitabine as
first- to third-line treatment in pretreated patients with
MBC [12]. The differences observed in OS between the
eribulin arm compared with capecitabine (15.9 vs.
14.5 months, respectively) were not statistically significant
(HR 0.88; 95 % CI 0.77–1.00; P = 0.056). Overall, the
safety and tolerability profiles of the treatments were
comparable: nausea was common with both treatments, in
addition, eribulin treatment more commonly led to neu-
tropenia, alopecia, leukopenia, and global peripheral neu-
ropathy; whereas capecitabine was more often associated
with hand-foot syndrome, and diarrhea. Similar improve-
ments in patients’ HRQoL over time (a prespecified sec-
ondary endpoint), measured by the global health status
(GHS)/quality of life (QoL) subscale of the European
Organisation for Research and Treatment of Cancer
Quality-of-life Questionnaire-Core 30 questions (EORTC
QLQ-C30), were observed in both treatment arms [12].
These two trials led to the approval of eribulin as a
monotherapy for patients with MBC who have previously
received at least one (European Union) or two (United
States) chemotherapeutic regimens for advanced/meta-
static disease, where prior therapy included an anthracy-
cline and a taxane in the adjuvant or metastatic setting
[13, 14].
Here we compare and further evaluate the clinical
impact of eribulin and capecitabine on patients’ symptoms/
side-effects, functioning, and HRQoL in study 301 [12] to
better understand the quality of survival in patients with
MBC. The analysis and interpretation of the results are
based on a model that posits biological factors associated
with a disease or its treatment lead to symptoms that
influence functional status, which then impacts on overall
HRQoL [15]. The specific objectives of the current post
hoc analyses were to:
(a) Compare physical symptoms, functional scores, and
GHS/QoL in patients treated with eribulin versus
capecitabine over time;
(b) Estimate the proportion of patients experiencing
clinically meaningful changes in HRQoL scales; and
(c) Compare the time to meaningful deterioration of
HRQoL in both treatment arms.
Subgroup analyses in patients with human epidermal
growth factor receptor 2 (HER2)-negative and triple-neg-
ative disease status were also performed.
Methods
Patients
The population enrolled (E7389-G000-301; ClinicalTri-
als.gov identifier: NCT00337103) has been previously
described [12]. In brief, women (aged C18 years) with
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histologically or cytologically confirmed breast cancer,
who had received B3 prior chemotherapy regimens (B2 for
advanced and/or metastatic disease) including prior therapy
with an anthracycline and a taxane, were eligible for study
inclusion.
Study design
The study was an open-label, 2-arm, parallel, multicenter,
phase 3 trial in which patients were stratified at random-
ization by geographic region (North America, Western
Europe, Eastern Europe, Latin America, South Africa, and
Asia) and HER2 status (positive, negative, or unknown).
Patients were randomized (1:1) to receive 21-day cycles
comprising eribulin mesylate 1.4 mg/m2 (equivalent to
1.23 mg/m2 of eribulin expressed as free base) intra-
venously over 2–5 min on days 1 and 8, or capecitabine
1.25 g/m2 orally twice daily on days 1–14. Patients
received study treatment until disease progression, unac-
ceptable toxicity, or patient/investigator request to dis-
continue. Grade 3 and 4 toxicities, including certain grade
2 toxicities with capecitabine, were managed by dose
modification including dose reduction, treatment interrup-
tion, and/or symptomatic treatment [12].
HRQoL assessment
HRQoL was a secondary endpoint in this study; the prin-
cipal prespecified HRQoL outcome was overall GHS/QoL
at week 6, and has been reported previously in brief [12].
The results reported here are based on additional post hoc
analyses of the study data.
HRQoL was assessed using EORTC QLQ-C30 (version
3.0) [16, 17] and the breast module-23 questions (QLQ-
BR23; version 1.0) [18]. The QLQ-C30 consists of 30
questions addressing five functional scales (cognitive,
emotional, physical, social, and role), nine symptom scales
(appetite loss, constipation, diarrhea, dyspnea, fatigue,
financial difficulties, insomnia, nausea and vomiting, and
pain), and one GHS/QoL scale. The EORTC QLQ-BR23
focuses on breast-cancer-specific issues and includes 23
questions addressing four functional (body image, future
perspective, sexual enjoyment, and sexual functioning) and
symptom scales (arm symptoms, breast symptoms, sys-
temic therapy side-effects, and upset by hair loss) [19]. All
scores for the EORTC QLQ-C30 and EORTC QLQ-BR23
were transformed to a scale from 0 to 100 [19]. Higher
scores in the functional scales and GHS/QoL represent a
superior level of functioning and better HRQoL, whereas
higher scores in the symptom scales or items represent
worse symptoms.
The questionnaires were administered at baseline, week
6, and months 3, 6, 12, 18, and 24, or until disease
progression or initiation of other antitumor treatment (in-
cluding those initiated after study termination). The base-
line EORTC questionnaires were completed in clinic
before randomization. Subsequent questionnaires were
completed in the clinic before any study-related procedures
for that visit and before tumor assessment results were
communicated to the patient. Patients were asked to com-
plete questionnaires at each clinic visit, even if they had
declined previously. Compliance was assessed by counting
completed questionnaires.
Statistical analyses
The HRQoL population was defined as patients with QoL
assessments at each time pointwithin the intent-to-treat (ITT)
population. Data were also analyzed separately for patients
with HER2-negative or triple-negative disease. Analysis of
patients with HER2-positive disease were not planned due to
the anticipated fewer number of patients in this subgroup.
Compliance for completing the EORTC questionnaires
was evaluated descriptively for each treatment group.
Pattern-mixture models were used to account for data
missing-not-at-random [20]. No imputation for missing
data was conducted. Mixed models on a set of covariates
based on expert opinion (baseline patient demographics
such as age, HER2 status, hormone receptor status, Eastern
Cooperative Oncology Group status, number of prior
chemotherapy regimens for advanced disease, number of
organs involved, visceral involvement, and disease-free
interval[1 year prior to study) were performed to estimate
the effect difference on repeated responses over a selected
period of time and between treatment arms. Longitudinal
analysis outcomes were expressed as least squares mean
and standard error. To test the difference in least squares
mean change from baseline between treatment arms, a
2-sided test with P B 0.05 (unadjusted for multiplicity)
was considered to be nominally statistically significant.
The minimally important difference (MID) was defined
as the smallest difference in scores between groups in the
scales of interest, which patients perceived as beneficial.
Literature-based threshold values for MID were used for
scales in the EORTC QLQ-C30 [21]. Because there are not
any published MIDs on the QLQ-BR23, a 10-point change
was considered consistent with previous estimates [22]. For
functional scales, an increase in change score from baseline
of C1 MID was defined as ‘‘improved,’’ a decrease of C1
MID was defined as ‘‘worsened,’’ and a change in either
direction of\1 MID was defined as ‘‘stable.’’ For symptom
scales, the same criteria were applied with reverse direc-
tion. Proportions of patients classified as ‘‘improved,’’
‘‘stable,’’ or ‘‘worsened’’ were calculated for each scale and
cycle. Tests of proportions were done using Chi squared or
Fisher’s exact tests, as appropriate. Cox analysis was used
Breast Cancer Res Treat
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Table 1 Baseline (a) patient characteristics and demographics, (b) health-related quality-of-life scores
(a)
Parameter Eribulin (n = 472) Capecitabine (n = 444) Total (n = 916)
Age, median, years (SD; range) 54.5 (10.3; 24.0–80.0) 53.0 (10.3; 26.0–80.0) 54.0 (10.3; 24.0–80.0)
Race, n (%)
White 424 (89.8) 402 (90.5) 826 (90.2)
Other 48 (10.2) 42 (9.5) 90 (9.8)
Body mass index, median (kg/m2) (SD; range) 26.7 (5.5; 12.7–62.1) 28.2 (5.8; 16.2–52.8) 27.8 (5.6; 12.7–62.1)
ECOG PS, n (%)
0 228 (48.3) 195 (43.9) 423 (46.2)
1 236 (50.0) 241 (54.3) 477 (52.1)
2 8 (1.7) 8 (1.8) 16 (1.7)
HER2 status, n (%)
Positive 80 (16.9) 73 (16.4) 153 (16.7)
Negative 309 (65.5) 301 (67.8) 610 (66.6)
Unknown 83 (17.6) 70 (15.8) 153 (16.7)
Triple-negative disease, n (%)
No 349 (73.9) 343 (77.3) 692 (75.5)
Yes 123 (26.1) 101 (22.7) 224 (24.5)
Number of prior chemotherapy regimens for metastatic disease, n (%)
1 130 (27.5) 122 (27.5) 252 (27.5)
2 271 (57.4) 255 (57.4) 526 (57.4)
C3 71 (15.0) 67 (15.1) 138 (15.1)
(b)
Domain Eribulina
(n = 554)
Capecitabineb
(n = 548)
EORTC QLQ-C30 (mean [SD])
GHS/QoL 56.3 (22.21) 54.7 (21.67)
Physical functioning 72.9 (21.00) 71.9 (20.68)
Role functioning 73.4 (27.68) 70.0 (29.27)
Emotional functioning 68.8 (23.00) 68.4 (24.15)
Cognitive functioning 81.5 (20.36) 81.4 (21.18)
Social functioning 75.4 (26.28) 73.4 (28.19)
Fatigue 37.4 (23.70) 38.0 (24.72)
Nausea and vomiting 10.0 (18.04) 10.1 (19.33)
Pain 31.8 (28.41) 32.9 (29.45)
Dyspnea 23.3 (27.56) 25.1 (29.45)
Insomnia 31.3 (29.34) 31.1 (30.98)
Appetite loss 20.8 (28.13) 23.2 (29.76)
Constipation 13.2 (23.43) 14.5 (26.23)
Diarrhea 8.1 (16.73) 8.2 (17.20)
Financial difficulties 32.6 (33.83) 30.1 (32.62)
EORTC QLQ-BR23 (mean [SD])
Body image 64.7 (28.73) 64.3 (30.23)
Sexual functioning 14.0 (20.34) 16.5 (22.51)
Sexual enjoyment 47.0 (25.27) 53.6 (26.13)
Future perspective 32.1 (31.29) 31.0 (30.84)
Systemic therapy side-effects 21.4 (16.16) 22.9 (17.17)
Breast symptoms 19.2 (22.74) 20.3 (24.86)
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to compare the MID changes for eribulin versus capecita-
bine (using a reference HR of 1). Adjusted values are stated
for the HR.
Time to symptom worsening (TSW) was defined as the
time until clinically meaningful deterioration by a specified
threshold for each patient-reported endpoint (such as, the
MID values) was observed. TSW was calculated for each
HRQoL scale using Kaplan–Meier curves. A proportional
hazards model (censoring on death, study drop-out, or
study discontinuation) was used to estimate adjusted HR
values of TSW plus each respective 95 % CI. For patients
with [1 TSW event or who deteriorated without
improvement, a generalized estimating equation was used
to estimate the relative probabilities of observing TSW
between treatment arms.
Results
HRQoL population
Of 1102 ITT patients randomized in study 301, 1062
(96.4 %) completed the EORTC questionnaire at baseline
and thus formed the HRQoL population. The populations
were broadly comparable between the treatment arms
(Table 1a). The baseline scores for both questionnaires were
similar (Table 1b). Across the symptom scales of the QLQ-
C30, patients in both treatment arms had worse scores on
fatigue, pain, insomnia, and financial difficulties (means
[30). The scores on QLQ-C30 functional scales were gen-
erally good (mean values around and above 70) with the
exception of GHS/QoL scale where mean scores around 50
suggest significant impact of disease [23]. However, the
breast-cancer-specific functional scales of the QLQ-BR23
showed impact on all domains (mean scores 32–65), in par-
ticular, on sexual functioning (mean score 14.0; Table 1b).
Compliance for completing the EORTC questionnaires
during the study was C85 % until 12 months, but was
lower at 18 and 24 months (73–83 %), and sample sizes
decreased due to study attrition (Table 2). Due to smaller
sample sizes, analyses after 6 months should be interpreted
with caution.
Treatment effects on symptoms
Exposure to both treatments during the study was compa-
rable between the two arms. Patients in the eribulin arm
received a median of six treatment cycles, whereas patients
in the capecitabine arm received a median of five treatment
cycles. Overall, 177 patients (eribulin: 32.5 %, capecita-
bine: 32.4 %) in either arm underwent dose reduction. The
most common reasons for dose reduction were neutropenia
in the eribulin arm (22.6 %), and palmar-plantar ery-
throdysesthesia syndrome (4.9 %) in the capecitabine arm.
During the course of the study, patients receiving
capecitabine had comparatively more-severe symptoms
(that is, higher symptom scores) for nausea and vomiting
(P\ 0.001; Fig. 1a and online resource Fig. S1; online
resource Table S1) and diarrhea (P\ 0.001) compared
with those treated with eribulin (Fig. 1a). The differences
were clinically significant, as a higher proportion of
patients who received capecitabine versus eribulin experi-
enced clinically meaningful worsening of nausea and
vomiting (MID 8; HR 1.177 [95 % CI 1.013, 1.367];
P\ 0.05) and diarrhea (MID 7; HR 1.189 [95 % CI 1.020,
1.385]; P\ 0.05; Fig. 1b). Typically, the differences
appeared to be greatest at 6 weeks, and declined thereafter.
In comparison, patients receiving eribulin had worse
mean scores for the systemic therapy side-effects symptom
scale (which included dry mouth, different tastes, irritated
eyes, feeling ill, hot flushes, headaches, and hair loss;
P\ 0.001), and upset by hair loss (P\ 0.05; Fig. 1a). A
higher proportion of patients treated with eribulin experi-
enced clinically meaningful worsening of systemic therapy
side-effects than those treated with capecitabine (MID 10;
HR 0.821 [95 % CI 0.707, 0.953]; P\ 0.01; Fig. 1b).
Table 1 continued
(b)
Domain Eribulina
(n = 554)
Capecitabineb
(n = 548)
Arm symptoms 25.1 (26.28) 26.4 (26.25)
Upset by hair loss 51.6 (38.01) 49.5 (38.31)
Data shown are mean (SD). The italicized values represent symptom scales
BR23 breast cancer module (23 questions), ECOG PS Eastern Cooperative Oncology Group performance status, EORTC European Organisation
for Research and Treatment of Cancer, GHS global health status, HER2 human endocrine receptor 2, QLQ-C30 quality-of-life questionnaire-
Core 30 questions, QoL quality of life, SD standard deviation
a n = 554 (QLQ-C30) or 536 (BR23)
b n = 548 (QLQ-C30) or 526 (BR23)
Breast Cancer Res Treat
123
The analysis of TSW supported the interpretation of the
MID thresholds. Patients receiving capecitabine had sig-
nificantly shorter TSW for nausea and vomiting (MID 8;
7.6 vs. 10.2 months; P\ 0.05), and diarrhea (MID 7; 8.4
vs. 11.5 months; P\ 0.05) than those treated with eribulin.
Similarly, patients treated with eribulin had significantly
shorter TSW for systemic therapy side-effects (MID 10;
7.6 vs. 9.7 months; P\ 0.05; Fig. 1c) compared with those
treated with capecitabine.
Treatment effects on patient functioning
In the longitudinal analyses, baseline HRQoL scores were
significantly associated with the change in HRQoL across
all EORTC scales (P\ 0.001); that is, worse baseline
scores were predictive of worse scores while on treatment.
There were no differences between the two treatment arms
in terms of impact on patients’ functioning over time, as
measured by changes in EORTC QLQ-C30 scores for
functional scales (Fig. 2a). However, patients receiving
eribulin had comparatively worse scores on the body image
(P\ 0.001) and sexual functioning scales (P\ 0.05),
measured by QLQ-BR23, than those receiving capecitabine
(Fig. 2a).
As indicated by the MID analysis, 10–35 % of patients
in both treatment arms experienced a clinically significant
worsening of their functioning, suggesting that the majority
of patients experienced stable or improved functioning. No
statistically significant differences over the course of the
study were observed between the treatment groups, except
that a higher proportion of patients receiving capecitabine
reported a meaningful worsening on the future perspective
scale than those receiving eribulin (MID 10; HR 1.173
[95 % CI 1.015, 1.356]; P\ 0.05; Fig. 2b).
In the ITT population, median TSW was similar for the
majority of the EORTC functional scales and the GHS/QoL
scale, with only 1–2 months’ difference between the treat-
ment arms. Patients receiving eribulin had significantly longer
TSW for body image (MID 10; 8.9 vs. 6.0 months; P\ 0.05)
and future perspective (MID10; 6.1vs. 4.7 months;P\ 0.05;
Fig. 2c) than those treated with capecitabine.
Treatment effects in patient subgroups by receptor
status
Overall, the results in the HER2-negative and triple-nega-
tive subgroups were similar to those in the overall popu-
lation in all analyses (data not shown). However, in
patients with triple-negative disease, significant differences
were observed in the TSW analyses. Importantly, TSW in
overall GHS/QoL was significantly longer in patients
treated with eribulin than those treated with capecitabine
(median time 6.2 vs. 6.0 months; P\ 0.01; Fig. 3). This
difference in median TSW may not appear clinically
meaningful, however, a separation of the Kaplan–Meier
survival curves is observed beyond 6 months, which is
likely to explain the statistically significant difference
between the two treatments. The median TSWs were also
longer in the eribulin arm compared with capecitabine arm
for fatigue (8.9 vs. 6.1 months; P\ 0.01), nausea and
vomiting (9.9 vs. 6.5 months; P\ 0.05), pain (8.1 vs.
5.4 months; P\ 0.05), and diarrhea (11.6 vs. 6.6 months;
P\ 0.01); as well as for the functional scales of body
image (6.7 vs. 6.0 months; P\ 0.05) and future perspec-
tive (6.0 vs. 4.8 months; P = 0.01). The TSW for systemic
therapy side-effects appeared shorter for patients treated
with eribulin than those receiving capecitabine, but this
difference was not statistically significant (4.9 vs.
7.2 months; P[ 0.05).
Discussion
In this phase 3 trial comparing eribulin with capecitabine in
patients with locally advanced or MBC previously treated
with an anthracycline and a taxane, significant differences
in physical symptoms/side-effects were observed, reflect-
ing the different toxicity profiles of the drugs. Patients
treated with capecitabine had worse scores, and more rapid
TSW for gastrointestinal symptoms (nausea and vomiting,
diarrhea), whereas patients treated with eribulin had worse
Table 2 Proportion of patients completing questionnaires at sched-
uled visits
Visit Eribulin (%)
(n = 554)
Capecitabine (%)
(n = 548)
Baseline 96.8 (536/554) 96.0 (526/548)
6 weeks 91.1 (450/494) 86.6 (419/484)
3 months 89.2 (329/369) 87.7 (299/341)
6 months 87.4 (167/191) 87.6 (170/194)
12 months 86.2 (56/65) 87.5 (63/72)
18 months 73.3 (22/30) 82.8 (24/29)
24 months 76.5 (13/17) 75.0 (15/20)
Data show patients who completed at least 1 question in the European
Organisation for Research and Treatment of Cancer questionnaire
among those who completed a baseline questionnaire. %, percent of
all patients who were scheduled to complete a questionnaire at visit
time (that is, patients who had not progressed or been censored)
cFig. 1 Effects of eribulin and capecitabine on physical symptom
scales of the EORTC QLQ-C30 and QLQ-BR23 a differences in
mean scores; b proportion of patients with worsened symptoms;
c differences in median time to symptom worsening
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scores for systemic therapy side-effects (dry mouth, food
and drink taste, eyes painful, hair loss, feeling ill/unwell,
hot flushes, headaches). These results were not only sta-
tistically significant in the longitudinal models but were
also clinically meaningful, as measured by the MID anal-
yses and TSW. Typically, the differences appeared to be
greatest at 6 weeks, and declined thereafter. This is in
alignment with the literature which suggests that during the
course of their disease, over 50 % of patients will experi-
ence nausea and vomiting, with a large proportion expe-
riencing these within the first week of treatment [10, 24].
Despite the above side-effects, the majority of patients
(65–90 %) in both treatment groups maintained or
improved their functioning relative to baseline. Based on
the group-level data over time using the pattern-mixture
model, patients treated with eribulin had worse body image
scores than those receiving capecitabine. While this finding
may seem contradictory to the TSW results, which show
that patients treated with eribulin compared with capeci-
tabine have longer TSW for body image, this can be
explained by the nature of the two different approaches.
TSW is an analytic approach that censors data on the time
to meaningful decline by a predefined threshold, whereas,
the longitudinal evaluation of the raw score change is not
censored. Therefore, while patients may have worse scores
for these domains in the eribulin arm, we observe that there
scores do not decline more rapidly compared to capecita-
bine treatment to a point of meaningful worsening.
Notably, in patients with triple-negative disease, eribulin
also demonstrated a significant delay in time to symptom
worsening of overall GHS/QoL, as well as fatigue, nausea
and vomiting, diarrhea, and pain when compared with
capecitabine. Although the 0.2-month improvement in
median TSW of overall GHS/QoL with eribulin compared
with capecitabine may not translate to an early clinical
benefit, a larger separation of the curves is observed
beyond 6 months, potentially due to a subset of patients
responding well to treatment.
Capecitabine is widely considered to be a chemotherapy
drug with manageable toxicity and a favorable risk:benefit
profile in patients with MBC [25, 26]. It is often used as a
first-line treatment in older and frail patients to achieve
disease control without significant side-effects [25, 27].
The capecitabine dose used in this study (1.25 g/m2 orally
twice-daily on days 1–14 per 21-day cycle) is approved by
the United States Food and Drug Administration, and has
been used in other clinical trials in patients with MBC [28–
30]. A lower dose of capecitabine, typically 1000 mg/m2
twice-daily for 14 days per 21-day cycle, has also been
investigated with similar efficacy but reportedly better
tolerability [28]. In our study, treatment exposure to
capecitabine was comparable to eribulin, with similar
proportions of patients in both arms experiencing dose
reduction. The observation that the impact of eribulin on
patient functioning and HRQoL, despite worse systemic
side-effect scores, is similar to that of capecitabine, is
therefore noteworthy, especially from a clinical
perspective.
HRQoL is increasingly being recognized as a valuable
endpoint of cancer care by payers, regulators, prescribers,
and patients. Patient-reported symptom endpoints have
prognostic value in clinical trials and support the impor-
tance of assessing the patient’s views in the development of
new therapies [31]. Therefore, while the development of
new cancer therapies should clearly focus on improving
efficacy, ideally in terms of OS, maximizing HRQoL is
also an important goal, particularly in the setting of
advanced disease. Where treatments have comparable
tumor-related outcomes, but competing toxicity profiles or
differing logistics of administration, HRQoL measurement
may help patients and clinicians to guide treatment deci-
sions [32]. The MID assessment described here was defined
as the smallest difference in scores between groups in the
scales of interest, which patients perceived as beneficial.
Therefore, by definition, MID-based improvements are
indicative of treatment benefit, and could guide physicians
in making treatment decisions.
The measurement of HRQoL and interpretation of
HRQoL outcomes are, however, challenging. A review of
clinical trials in patients with MBC that included mea-
surement of HRQoL concluded that this assessment does
bFig. 2 Effects of eribulin and capecitabine on function scales of the
EORTC QLQ-C30 and QLQ-BR23. a differences in mean scores;
b proportion of patients with worsened symptoms; c differences in
median time to symptom worsening
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Fig. 3 Effects of eribulin and capecitabine, in terms of time to
symptom worsening, on overall global health status/quality-of-life
scale of the EORTC QLQ-C30 in patients with triple-negative disease
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not always provide additional information that is not
already clear from other clinical outcomes, such as toxicity
[32]. Indeed, in the current study, HRQoL changes in
individual symptom scales of the EORTC QLQ-C30 and
QLQ-BR23 instruments detected differences on patient
reporting corresponding to the known adverse event profile
for each agent. Nevertheless, no differences between the
two treatments were observed for functional and overall
HRQoL outcomes. HRQoL instruments may, however,
lack sufficient precision to detect differences between
treatments among a relatively homogeneous clinical trial
population [33]. Patients may also find it easier to rate
individual symptom scales accurately than a global
HRQoL scale [33].
Chemotherapy-induced gastrointestinal symptoms
(nausea, vomiting, and diarrhea) are common side-effects
that can be debilitating for patients [10, 11]. Importantly,
diarrhea can interfere with cancer treatment by forcing
dose delays or reductions [34]. Diarrhea is one of the
principal dose-limiting toxicities of capecitabine and this is
reflected in the study findings, with eribulin being associ-
ated with comparatively lower symptom scores for diarrhea
as well as a lower proportion of patients reporting wors-
ening diarrhea, and a longer TSW for this symptom.
Patients on capecitabine reported worse nausea/vomiting
than those on eribulin, whereas the scale scores for other
systemic therapy side-effects were significantly worse with
eribulin. Together, this information will contribute to dis-
cussions with patients during the treatment decision-mak-
ing process. Review of the observed toxicity experience of
patients in this study (any grade adverse event) were con-
sistent with the patient-reported symptom experience
reported in this study: patients on capecitabine experienced
more adverse events of diarrhea (29 vs. 14 % for eribulin),
vomiting (17 vs. 12 % for eribulin), anorexia (15 vs. 13 %
for eribulin) and nausea (24 vs. 22 % for eribulin) whereas
patients on eribulin experienced more adverse events of
alopecia (35 vs. 18 % for capecitabine) and fatigue (17 vs.
15 % for capecitabine) [35].
This HRQoL analysis has several strengths. It is based
on data from a large-scale, randomized, clinical trial, using
2 well-validated instruments for data collection—the
EORTC QLQ-C30 instrument and its breast-cancer-speci-
fic supplementary module, QLQ-BR23. Compliance was
good throughout most of the study (C80 % to the 12-month
time point). Content validity for the symptom scales used
has been validated in patients with advanced breast cancer
or MBC in a phase 2 study of eribulin (E7389-G000-211;
ClinicalTrials.gov identifier: NCT00246090) [36]. How-
ever, the analyses may be limited by the sample size for
QoL analysis that decreased sharply from the 12-month
time point due to death or discontinuation from the parent
study, which is frequently observed in the metastatic
setting due to the natural history of the disease. It should
also be noted that the assessment instruments used for the
study do not specifically capture the symptoms particularly
related to capecitabine (namely, ‘‘hand-foot syndrome’’)
and eribulin (e.g., peripheral neuropathy).
In conclusion, the majority of patients with pretreated
locally advanced or MBC who were treated with either
eribulin or capecitabine did not experience an overall dete-
rioration in functioning or GHS/QoL. Eribulin and capeci-
tabine had similar effects on patients’ HRQoL scores
reflecting the known side-effect profiles of these two agents.
Alongwith the efficacyand toxicity findings of study301 [12]
and study 305/EMBRACE [11], the HRQoL results from this
study 301 analyses may help patients with MBC and their
oncologists to make more informed treatment decisions.
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